Intragenic ERBB2 kinase mutations in tumours

Cited by (802)

Items 101–200 of 802

1. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
   Gonzales, Andrea J., Hook, Kenneth E., Althaus, Irene W., Ellis, Paul A., Trachet, Erin, Delaney, Amy M., Harvey, Patricia J., Ellis, Teresa A., Amato, Danielle M., Nelson, James M. et al. · 2008 · Molecular Cancer Therapeutics
2. Molecular pathways and therapeutic targets in lung cancer
   Shtivelman, Emma, Hensing, Thomas, Simon, George R., Dennis, Phillip A., Otterson, Gregory A., Bueno, Raphael, Salgia, Ravi · 2014 · Oncotarget
3. Targeting the Molecular Chaperone Heat Shock Protein 90 Provides a Multifaceted Effect on Diverse Cell Signaling Pathways of Cancer Cells
   Wanping Xu, Len Neckers · 2007 · Clinical Cancer Research
4. Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2
   Scott A. Foster, Daniel M. Whalen, Ayşegül Özen, Matthew J. Wongchenko, Jianping Yin, Ivana Yen, Gabriele Schaefer, John D. Mayfield, Juliann Chmielecki, Philip J. Stephens et al. · 2016 · Cancer Cell
5. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery
   N THOMPSON, J LYONS · 2005 · Current Opinion in Pharmacology
6. HER2 aberrations in cancer: Implications for therapy
   Min Yan, Barbara A. Parker, Richard B. Schwab, Razelle Kurzrock · 2014 · Cancer Treatment Reviews
7. HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium
   Rathi Narayana Pillai, Madhusmita Behera, Lynne D. Berry, Mike R. Rossi, Mark G. Kris, Bruce Evan Johnson, Paul A. Bunn, Suresh S. Ramalingam, Fadlo R. Khuri · 2017 · Cancer
8. Molecular biology of lung cancer: Clinical implications
   Kwun Meng Fong, John Dorrance Minna · 2002 · Clinics in Chest Medicine
9. Pyrotinib in HER2 -Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study
   Caicun Zhou, Xingya Li, Qiming Wang, Guanghui Gao, Yiping Zhang, Jianhua Chen, Yongqian Shu, Yanping Hu, Yun Fan, Jian Fang et al. · 2020 · Journal of Clinical Oncology
10. An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance
    Mitra, Doyel, Brumlik, Michael J., Okamgba, Stella U., Zhu, Yun, Duplessis, Tamika T., Parvani, Jenny G., Lesko, Samuel M., Brogi, Edi, Jones, Frank E. · 2009 · Molecular Cancer Therapeutics
11. Drivers and passengers
    Daniel A. Haber, Jeff Settleman · 2007 · Nature
12. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors
    Gandhi, Leena, Bahleda, Rastislav, Tolaney, Sara M., Kwak, Eunice L., Cleary, James M., Pandya, Shuchi S., Hollebecque, Antoine, Abbas, Richat, Ananthakrishnan, Revathi, Berkenblit, Anna et al. · 2014 · Journal of Clinical Oncology
13. Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations
    Mariona Riudavets, Ivana Sullivan, Pamela Abdayem, David Planchard · 2021 · ESMO Open
14. EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
    Alex Friedlaender, Vivek Subbiah, Alessandro Russo, Giuseppe Luigi Banna, Umberto Malapelle, Christian D. Rolfo, Alfredo Addeo · 2021 · Nature Reviews Clinical Oncology
15. HER2 YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy
    Samanthi A. Perera, Danan Li, Takeshi Shimamura, Maria Gabriela Raso, Hongbin Ji, Liang Chen, Christa L. Borgman, Sara Zaghlul, Kathleyn A. Brandstetter, Shigeto Kubo et al. · 2009 · Proceedings of the National Academy of Sciences
16. Validation of a Next-Generation Sequencing Assay for Clinical Molecular Oncology
    Catherine E. Cottrell, Hussam Al‐Kateb, Andrew J. Bredemeyer, Eric James Duncavage, David H. Spencer, Haley Abel, Christina M. Lockwood, Ian S. Hagemann, Stephanie M. O’Guin, Lauren C. Burcea et al. · 2013 · Journal of Molecular Diagnostics
17. Lung cancer in never smokers: Disease characteristics and risk factors
    Athanasios G. Pallis, Konstantinos Nikolaos Syrigos · 2013 · Critical Reviews in Oncology/Hematology
18. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence
    Ou, Sai-Hong Ignatius · 2012 · Critical Reviews in Oncology/Hematology
19. Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors
    Jänne, Pasi A., Boss, David S., Camidge, D. Ross, Britten, Carolyn D., Engelman, Jeffrey A., Garon, Edward B., Guo, Feng, Wong, Steven, Liang, Jane, Letrent, Stephen et al. · 2011 · Clinical Cancer Research
20. Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: Mutations are mainly present in adenocarcinomas with bronchioloalveolar features
    Buttitta, Fiamma, Barassi, Fabio, Fresu, Giuseppina, Felicioni, Lara, Chella, Antonio, Paolizzi, Diego, Lattanzio, Giuseppe, Salvatore, Simona, Camplese, Pier P., Rosini, Sandra et al. · 2006 · International Journal of Cancer
21. Resistance to HER2-directed antibodies and tyrosine kinase inhibitors
    Joan T. Garrett, Carlos L. Arteaga · 2011 · Cancer Biology & Therapy
22. Frequency of Driver Mutations in Lung Adenocarcinoma from Female Never-Smokers Varies with Histologic Subtypes and Age at Diagnosis
    Yang Zhang, Yihua Sun, Yunjian Pan, Chenguang Li, Lei Shen, Yuan Li, Xiaoyang Luo, Ting Ye, Rui Wang, Haichuan Hu et al. · 2012 · Clinical Cancer Research
23. Activating HER2 mutations as emerging targets in multiple solid cancers
    Claire M. Connell, Gary Joseph Doherty · 2017 · ESMO Open
24. Breast Cancer — Loss of PTEN Predicts Resistance to Treatment
    Pier Paolo Pandolfi · 2004 · New England Journal of Medicine
25. Mutations of the epidermal growth factor receptor in non-small cell lung cancer – Search and destroy
    S.K. Chan, William John Gullick, Mark E. Hill · 2005 · European Journal of Cancer
26. Somatic alterations in the human cancer genome
    Barbara A. Weir, Xiaojun Zhao, Matthew M. Meyerson · 2004 · Cancer Cell
27. EGFR, HER2 and VEGF Pathways
    Michael F. Press, Heinz‐Josef Lenz · 2007 · Drugs
28. A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer
    Variant Interpretation for Cancer Consortium, Wagner, Alex H., Walsh, Brian, Mayfield, Georgia, Tamborero, David, Sonkin, Dmitriy, Krysiak, Kilannin, Deu-Pons, Jordi, Duren, Ryan P., Gao, Jianjiong et al. · 2020 · Nature Genetics
29. Mechanisms of lapatinib resistance in HER2-driven breast cancer
    Valentina D’Amato, Lucia Raimondo, Luigi Formisano, Mario Giuliano, Sabino De Placido, Roberta Rosa, Roberto Bianco · 2015 · Cancer Treatment Reviews
30. EGFR and erbB2 mutation status in Japanese lung cancer patients
    Hidefumi Sasaki, Shigeki Shimizu, Katsuhiko Endo, Minoru Takada, Masaaki Kawahara, Hisaichi Tanaka, Akihide Matsumura, Keiji Iuchi, Hiroshi Haneda, Eriko Suzuki et al. · 2005 · International Journal of Cancer
31. Ethnic Differences in Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    Emiliano Calvo, Jose M Baselga · 2006 · Journal of Clinical Oncology
32. The HER family and cancer: emerging molecular mechanisms and therapeutic targets
    Natalia V. Sergina, Mark M. Moasser · 2007 · Trends in Molecular Medicine
33. Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms
    Toshimitsu Yamaoka, Motoi Ohba, Tohru Ohmori · 2017 · International Journal of Molecular Sciences
34. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers
    Tomizawa, Kenji, Suda, Kenichi, Onozato, Ryoichi, Kosaka, Takayuki, Endoh, Hideki, Sekido, Yoshitaka, Shigematsu, Hisayuki, Kuwano, Hiroyuki, Yatabe, Yasushi, Mitsudomi, Tetsuya · 2011 · Lung Cancer
35. High ERK Protein Expression Levels Correlate with Shorter Survival in Triple-Negative Breast Cancer Patients
    Chandra Bartholomeusz, Ana Maria Gonzalez-Angulo, Ping Liu, Naoki Hayashi, Ana M. Lluch, Jaime Ferrer-Lozano, Gabriel N. Hortobágyi · 2012 · The Oncologist
36. Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma
    Heini J. Lassus, Harri J. Sihto, Arto Leminen, Heikki Joensuu, Jorma J Isola, Nina N. Nupponen, Ralf C. Bützow · 2006 · Journal of Molecular Medicine
37. MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors
    Takafumi Kubo, Hiromasa Yamamoto, William Wirt Lockwood, Ilse Valencia, Junichi Soh, Michael Peyton, Masaru Jida, Hiroki Otani, Tetsuya Fujii, Mamoru Ouchida et al. · 2008 · International Journal of Cancer
38. Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib
    Rama Krishna Kancha, Nikolas C. C. von Bubnoff, Natalie Bartosch, Christian Peschel, Richard Alan Engh, Justus Duyster · 2011 · PLoS ONE
39. Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: Activation of MET as one mechanism for drug resistance
    Rebekka Krumbach, Julia B. Schüler, Michael Hofmann, Torsten Giesemann, Heinz‐Herbert Fiebig, Thomas L. Beckers · 2011 · European Journal of Cancer
40. The Role of Human Epidermal Growth Factor Receptor 2 as a Prognostic Factor in Lung Cancer: A Meta-Analysis of Published Data
    Lingxiang Liu, Xiaoyan Shao, Wen Gao, Jianling Bai, Rongsheng Wang, Puwen Huang, Yongmei Yin, Ping Liu, Yongqian Shu · 2010 · Journal of Thoracic Oncology
41. Evidence that MIG-6 is a tumor-suppressor gene
    Y-W Zhang, Ben Staal, Y Su, P J Swiatek, Ping Zhao, B Cao, James H. Resau, Robert E. Sigler, Roderick Terry Bronson, George F. Vande Woude · 2006 · Oncogene
42. Identification of Metastasis-Associated Receptor Tyrosine Kinases in Non–Small Cell Lung Cancer
    Carsten Müller‐Tidow, Sven Diederichs, Etmar Bulk, Thorsten Pohle, Björn Steffen, Joachim Schwäble, Sylvia Plewka, Michael Thomas, Ralf Metzger, Paul M. Schneider et al. · 2005 · Cancer Research
43. Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014
    Daniel Morgensztern, Meghan J. Campo, Suzanne Eleanor Dahlberg, Robert Charles Doebele, Edward B. Garon, David E. Gerber, Sarah B. Goldberg, Peter S. Hammerman, Rebecca Suk Heist, Thomas A. Hensing et al. · 2015 · Journal of Thoracic Oncology
44. Targeting the NF-κB Pathway in Cancer Therapy
    Derek J. Erstad, James C. Cusack · 2013 · Surgical Oncology Clinics of North America
45. Non–Small-Cell Lung Cancer and Ba/F3 Transformed Cells Harboring the ERBB2 G776insV_G/C Mutation Are Sensitive to the Dual-Specific Epidermal Growth Factor Receptor and ERBB2 Inhibitor HKI-272
    Takeshi Shimamura, Hongbin Ji, Yuko Minami, Roman Kurt Thomas, April M. Lowell, Kinjal Shah, Heidi E. Greulich, Karen A. Glatt, Matthew M. Meyerson, Geoffrey Ira Shapiro et al. · 2006 · Cancer Research
46. Relapsed Classic E-Cadherin ( CDH1 )–Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 ( ERBB2 ) Gene Mutations
    Ross, Jeffrey S., Wang, Kai, Sheehan, Christine E., Boguniewicz, Ann B., Otto, Geoff, Downing, Sean R., Sun, James, He, Jie, Curran, John A., Ali, Siraj et al. · 2013 · Clinical Cancer Research
47. Role of ErbB4 in Breast Cancer
    Maria Sundvall, Kristiina Iljin, Sami K. Kilpinen, Henri Sara, Olli Kallioniemi, Klaus Elenius · 2008 · Journal of Mammary Gland Biology and Neoplasia
48. EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation
    Torsten Trowe, Sotiria Boukouvala, Keith Calkins, Richard E. Cutler, Ryan Fong, Roel Peter Funke, Steven B. Gendreau, Yong D. Kim, Nicole Miller, John R. Woolfrey et al. · 2008 · Clinical Cancer Research
49. Mutation of ERBB2 Provides a Novel Alternative Mechanism for the Ubiquitous Activation of RAS-MAPK in Ovarian Serous Low Malignant Potential Tumors
    Michael S. Anglesio, Jeremy M. Arnold, Joshy George, Anna V. Tinker, Richard W. Tothill, Nicola Waddell, Lisa A. Simms, Bianca Locandro, Sián Fereday, Nadia Traficante et al. · 2008 · Molecular Cancer Research
50. Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors
    Kosaka, Takayuki, Tanizaki, Junko, Paranal, Raymond M., Endoh, Hideki, Lydon, Christine, Capelletti, Marzia, Repellin, Claire E., Choi, Jihyun, Ogino, Atsuko, Calles, Antonio et al. · 2017 · Cancer Research
51. Novel Therapeutic Targets in Non-small Cell Lung Cancer
    Filip Jankú, Ignacio Garrido‐Laguna, Lubos B. Petruzelka, David J. Stewart, Razelle Kurzrock · 2011 · Journal of Thoracic Oncology
52. Genomic alterations of ERBB receptors in cancer: clinical implications
    Rosalin Mishra, Ariella B. Hanker, Joan T. Garrett · 2017 · Oncotarget
53. Advances in Targeting Human Epidermal Growth Factor Receptor-2 Signaling for Cancer Therapy
    Funda Meric‐Bernstam, Mien‐Chie Hung · 2006 · Clinical Cancer Research
54. Response of Some Head and Neck Cancers to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors May Be Linked to Mutation ofERBB2rather thanEGFR
    Ezra E.W. Cohen, Mark William Lingen, Leslie E. Martin, Patricia L. Harris, Brian W. Brannigan, Sara M. Haserlat, Ross A. Okimoto, Dennis C. Sgroi, Sonika M Dahiya, Beth Muir et al. · 2005 · Clinical Cancer Research
55. The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies
    Jaclyn A. Freudenberg, Qiang Wang, Makoto Katsumata, Jeffrey A. Drebin, Izumi Nagatomo, Mark Irwin Greene · 2009 · Experimental and Molecular Pathology
56. Exclusive mutation in epidermal growth factor receptor gene, HER‐2, and KRAS, and synchronous methylation of nonsmall cell lung cancer
    Makoto Suzuki, Hisayuki Shigematsu, Toshihiko Iizasa, Kenzo Hiroshima, Yukio Nakatani, John Dorrance Minna, Adi F. Gazdar, Takehiko Fujisawa · 2006 · Cancer
57. The effects of environmental chemical carcinogens on the microRNA machinery
    Alberto Izzotti, Alessandra Pulliero · 2014 · International Journal of Hygiene and Environmental Health
58. Linkage between EGFR family receptors and nuclear factor kappaB (NF‐κB) signaling in breast cancer
    Debajit Kumar Biswas, James Dirk Iglehart · 2006 · Journal of Cellular Physiology
59. Novel Germline Mutation in the Transmembrane Domain of HER2 in Familial Lung Adenocarcinomas
    Hiromasa Yamamoto, Koichiro Higasa, Masakiyo Sakaguchi, Kazuhiko Shien, Junichi Soh, Koichi Ichimura, Masashi Furukawa, Shinsuke Hashida, Kazunori Tsukuda, Nagio Takigawa et al. · 2013 · JNCI Journal of the National Cancer Institute
60. Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability
    Se Hun Kang, Keon Wook Kang, Kyung‐Hee Kim, B. Kwon, Seok-Ki Kim, Ho‐Young Lee, Sun‐Young Kong, Eun Sook Lee, Sang‐Geun Jang, Byong Chul Yoo · 2008 · BMC Cancer
61. Optimizing Mutation and Fusion Detection in NSCLC by Sequential DNA and RNA Sequencing
    Danielle B. Cohen, Liesbeth M. Hondelink, Nienke Solleveld‐Westerink, Sandra M. Kolkman-Uljee, Dina Ruano, Anne‐Marie Cleton-Jansen, Jan H. von der Thüsen, S.R.S. Ramai, Pieter E. Postmus, J. F. Graadt van Roggen et al. · 2020 · Journal of Thoracic Oncology
62. Transcriptomic characterization of fibrolamellar hepatocellular carcinoma
    Elana P. Simon, Catherine A. Freije, Benjamin A. Farber, Gadi Lalazar, David G. Darcy, Joshua N. Honeyman, Rachel C. Chiaroni-Clarke, Brian D. Dill, Henrik Molina, Umesh Kumar Bhanot et al. · 2015 · Proceedings of the National Academy of Sciences
63. Consensus for HER2 alterations testing in non-small-cell lung cancer
    Shengxiang Ren, Jiong Wang, Jianming Ying, Tetsuya Mitsudomi, Daniel Lee, Zengwu Wang, Q. Chu, Philip C. Mack, Ying Cheng, Jianchun Duan et al. · 2022 · ESMO Open
64. Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives
    Haiyang Guo, Jun Zhang, Chao Qin, Hang Yan, Tao Liu, Haiyang Hu, Shengjie Tang, Shoujun Tang, Haining Zhou · 2022 · Cells
65. Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK
    Sacha I. Rothschild · 2015 · Cancers
66. The frequency and clinical impact of HER2 alterations in lung adenocarcinoma
    Eun‐Kyung Kim, Kyunga Kim, Chang Young Lee, Hyo Sup Shim · 2017 · PLoS ONE
67. Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung
    Yukihiro Yoshida, Tatsuhiro Shibata, Akiko Kokubu, Koji Tsuta, Yoshihiro Matsuno, Yae Kanai, Hisao Asamura, Ryosuke Tsuchiya, Setsuo Hirohashi · 2005 · Lung Cancer
68. LIV-1 Promotes Prostate Cancer Epithelial-to-Mesenchymal Transition and Metastasis through HB-EGF Shedding and EGFR-Mediated ERK Signaling
    Hui-Wen Lue, Xiaojian Yang, Ruoxiang Wang, Weiping Qian, Roy Z. H. Xu, Robert H. Lyles, Adeboye O. Osunkoya, Binhua Peter Zhou, Robert L. Vessella, Majd Zayzafoon et al. · 2011 · PLoS ONE
69. The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272
    Yuko Minami, Takeshi Shimamura, Kinjal Shah, Thomas LaFramboise, Karen A. Glatt, Elizabeth Liniker, Christa L. Borgman, Henry J. Haringsma, William W. Feng, Barbara A. Weir et al. · 2007 · Oncogene
70. Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene
    Takayuki Fukui, Yasushi Yatabe, Yoshihisa Kobayashi, Kenji Tomizawa, Simon Ito, Shunzo Hatooka, Keitaro Matsuo, Tetsuya Mitsudomi · 2012 · Lung Cancer
71. Somatic mutations of theERBB4kinase domain in human cancers
    Young Hwa Soung, Jong Woo Lee, Su Young Kim, Young Pil Wang, Keon Hyun Jo, Seok Whan Moon, Won Sang Park, Suk Woo Nam, Jung Young Lee, Nam Jin Yoo et al. · 2005 · International Journal of Cancer
72. Molecular Imaging in the Development of Cancer Therapeutics
    Johannes G. Czernin, Wolfgang Weber, Harvey R. Herschman · 2006 · Annual Review of Medicine
73. Targeting HER2 Alterations in Non–Small-Cell Lung Cancer: A Comprehensive Review
    Jing Zhao, Yang Xia · 2020 · JCO Precision Oncology
74. HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib
    Sai‐Hong Ignatius Ou, Alexa Betzig Schrock, Eduard Valeryevich Bocharov, Samuel Jacob Klempner, Carolina Kawamura Haddad, Gary Steinecker, Melissa Lynne Johnson, Barbara Jennifer Gitlitz, Jon Chung, Paulo Vidal Campregher et al. · 2016 · Journal of Thoracic Oncology
75. Ultraviolet Radiation and Basal Cell Carcinoma: An Environmental Perspective
    Yan Teng, Yong Yu, Sujing Li, Youming Huang, Danfeng Xu, Xiaohua Tao, Yibin Fan · 2021 · Frontiers in Public Health
76. Cancer driver mutations in protein kinase genes
    Ali Torkamani, Gennady M. Verkhivker, Nicholas J. Schork · 2008 · Cancer Letters
77. Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma
    Mahmoud A.L. Sheikh Ali, Mehmet Gündüz, Hitoshi Nagatsuka, Esra Gündüz, Beyhan Cengiz, Kunihiro Fukushima, LEVENT BEKIR BEDER, Kadir Demircan, Masae Fujii, Noboru Yamanaka et al. · 2008 · Cancer Science
78. Genetic Classification of Lung Adenocarcinoma Based on Array-Based Comparative Genomic Hybridization Analysis: Its Association with Clinicopathologic Features
    Tatsuhiro Shibata, Satomi Uryu, Akiko Kokubu, Fumie Hosoda, Misao Ohki, Tokuki Sakiyama, Yoshihiro Matsuno, Ryosuke Tsuchiya, Yae Kanai, Tadashi Kondo et al. · 2005 · Clinical Cancer Research
79. The Impact of Genomic Changes on Treatment of Lung Cancer
    Stephanie Cardarella, Bruce Evan Johnson · 2013 · American Journal of Respiratory and Critical Care Medicine
80. Emerging evidence and treatment paradigm of non-small cell lung cancer
    Si‐Yang Maggie Liu, Mei-Mei Zheng, Yi Pan, Si‐Yang Maggie Liu, Yangqiu Li, Yi-Long Lung Cancer Wu · 2023 · Journal of Hematology & Oncology
81. Targeted Therapies for Lung Cancer
    Jill E. Larsen, Tina Cascone, David E. Gerber, John Victor Heymach, John Dorrance Minna · 2011 · The Cancer Journal
82. Efficacy and Safety of Single-Agent Pertuzumab, a Human Epidermal Receptor Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer
    Roy S. Herbst, Angela M. Davies, Ronald B. Natale, Thao P. Dang, Joan H. Schiller, Linda L. Garland, Vincent A. Miller, David S. Mendelson, Annick D. Van den Abbeele, Yulia V. Melenevsky et al. · 2007 · Clinical Cancer Research
83. The Genomics of Lung Adenocarcinoma: Opportunities for Targeted Therapies
    Heidi E. Greulich · 2010 · Genes & Cancer
84. Targeting HER2 in the treatment of non-small cell lung cancer
    Nataliya Mar, James J. Vredenburgh, Jeffrey S. Wasser · 2015 · Lung Cancer
85. Oncogenic Alterations in ERBB2/HER2 Represent Potential Therapeutic Targets Across Tumors From Diverse Anatomic Sites of Origin
    Juliann Chmielecki, Jeffrey S. Ross, Kai Wang, Garrett Michael Frampton, Gary A. Palmer, Siraj Mahamed Ali, Norma Alonzo Palma, Deborah Morosini, Vincent A. Miller, Roman Yelensky et al. · 2014 · The Oncologist
86. BRAF and c-kit gene copy number in mutation-positive malignant melanoma
    Carlynn Willmore‐Payne, Joseph A. Holden, Sharon L. Hirschowitz, Lester James Layfield · 2006 · Human Pathology
87. Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications
    Sherri Z. Millis, Zoran Gatalica, Josiah Winkler, Semir Vranić, Jeffery Kimbrough, Sandeep K. Reddy, Joyce O’Shaughnessy · 2015 · Clinical Breast Cancer
88. Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck
    Carlynn Willmore‐Payne, Joseph A. Holden, Lester James Layfield · 2006 · Modern Pathology
89. Molecular Diagnostic Testing in Malignant Gliomas: A Practical Update on Predictive Markers
    Stephen S. F. Yip, Anthony John Iafrate, David N. Louis · 2008 · Journal of Neuropathology & Experimental Neurology
90. Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains
    Chenguang Li, Yihua Sun, Rong Fang, Xiangkun Han, Xiaoyang Luo, Rui Wang, Yunjian Pan, Haichuan Hu, Yang Zhang, William J. Pao et al. · 2011 · Journal of Thoracic Oncology
91. The Hedgehog Signaling Networks in Lung Cancer: The Mechanisms and Roles in Tumor Progression and Implications for Cancer Therapy
    Yoshinori Abe, Nobuyuki Tanaka · 2016 · BioMed Research International
92. Mutual Repression by Bantam miRNA and Capicua Links the EGFR/MAPK and Hippo Pathways in Growth Control
    Héctor Herranz, Xin Hong, Stephen Michael Cohen · 2012 · Current Biology
93. Epidermal Growth Factor Receptor Mutation in Lung Cancer are Linked to Bronchioloalveolar Differentiation
    Hélène Blons, Jean-François Côté, Delphine Le Corre, Marc Riquet, Elizabeth Fabre, Pierre Laurent‐Puig, Claire J. Danel · 2006 · The American Journal of Surgical Pathology
94. The status and role of ErbB receptors in human cancer
    Ivo Überall, Zdeněk Kolář, Radek Trojanec, Jitka Berkovcová, Marián Hajdúch · 2008 · Experimental and Molecular Pathology
95. Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis
    David J. Riese, Richard M. Gallo, Jeffrey E. Settleman · 2007 · BioEssays
96. ERBB2 -Mutated Metastatic Non–Small Cell Lung Cancer: Response and Resistance to Targeted Therapies
    Jody C. Chuang, Henning Stehr, Ying Liang, Millie Snigdha Das, Jane Q. Huang, Maximilian Diehn, Heather A. Wakelee, Joel W. Neal · 2017 · Journal of Thoracic Oncology
97. ErbB2 Pathway Activation upon Smad4 Loss Promotes Lung Tumor Growth and Metastasis
    Jian Liu, Sung-Nam Cho, Bindu H. Akkanti, Nili Jin, Jianqiang Mao, Weiwen Long, Tenghui Chen, Yiqun Zhang, Ximing Tang, Ignacio I. Wistub et al. · 2015 · Cell Reports
98. Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer
    Prithviraj Bose, Howard Ozer · 2009 · Expert Opinion on Investigational Drugs
99. Prognostic and predictive biomarkers in lung cancer. A review
    Erik Thunnissen, Kimberly Van der Oord, Michael den Bakker · 2014 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
100. Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment
     Grit Sophie Herter-Sprie, Heidi E. Greulich, Kwok‐Kin Wong · 2013 · Frontiers in Oncology